Biocon Q1 net profit falls 95% to Rs 31 crore

Biocon’s consolidated net profit plummeted by 95% to Rs 31 crore in the June quarter, with total revenue declining to Rs 4,022 crore. Despite this, operating revenue increased by 15% YoY, driven by Biosimilars and CRDMO gains. A recent QIP has strengthened the balance sheet, enabling increased ownership in Biocon Biologics and positioning the company…

Read More

Foreign investments flood Asia: $25.7 billion flows to Taiwan, South Korea; Thailand snaps 9-month losing streak

Asian equities experienced a resurgence in July, fueled by AI interest and improved US trade relations. Taiwan saw a record $7.78 billion inflow, while South Korea had its best month since February. Thailand ended a nine-month outflow streak, though challenges remain. India, Indonesia, and the Philippines saw outflows, while Vietnam attracted funds due to strong…

Read More

Donald Trump’s tariff tussle: Duties on Indian pharma would be ‘counterproductive’; America may take at least 3 years to match India’s scale, says Pharmexcil

Despite increased tariffs on Indian imports, the US has temporarily exempted the pharmaceutical sector, recognizing India’s critical role in supplying affordable medicines. Pharmexcil emphasizes that tariffs on Indian pharma would harm American consumers, as Indian companies produce low-cost generics. India supplies over 40% of US generic medicines, maintaining high quality standards with numerous FDA-approved facilities.

Read More